公开(公告)号：US20240294634A1

公开(公告)日：2024-09-05

申请号：US17768484

申请日：2020-10-13

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K2039/507

Abstract: This invention relates to the use of a NKG2A-neutralizing agent and an antibody that inhibits human ILT2 to treat cancer, particularly a head and neck squamous cell carcinoma (HNSCC), a lung cancer, optionally an NSCLC, a renal cell carcinoma, a colorectal carcinoma, a urothelial cancer or an ovarian cancer.

公开(公告)号：US20220025045A1

公开(公告)日：2022-01-27

申请号：US17418271

申请日：2019-12-20

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.

公开(公告)号：US20220025056A1

公开(公告)日：2022-01-27

申请号：US17418269

申请日：2019-12-20

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.